Stocks of the Hour: Origin Energy, Sunstone Metals, Chimeric Therapeutics
Stocks of the Hour: Origin Energy, Sunstone Metals, Chimeric Therapeutics
Chimeric Therapeutics (ASX:CHM) announced that the 1st patient has been dosed in the Phase 1B CHM 1101 in their brain cancer clinical trial. The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data. Shares are trading flat at 2.9 cents.To register for Friday's webinar click here.
要注册参加周五的网络研讨会，请单击此处。
Origin Energy (ASX:ORG) announced that the Brookfield-led consortium of investors and EIG has significantly increased the cash consideration to best and final proposal of $9.53 per share. In response, Origin Chairman Scott Perkins said, "the revised consideration is now above the top end of the Independent Expert's 30 June 2023 valuation range, allowing all shareholders to receive a certain cash value for their Origin shares." Shares are trading 1.54 per cent lower at $8.93.
Origin Energy (ASX: ORG) 宣布，布鲁克菲尔德领导的投资者财团和EIG已将现金对价大幅提高至每股9.53美元的最佳和最终提案。对此，Origin董事长斯科特·珀金斯表示：“修订后的对价目前高于独立专家2023年6月30日估值区间的最高水平，允许所有股东从Origin股票中获得一定的现金价值。”股价下跌1.54％，至8.93美元。
Sunstone Metals (ASX:STM) announced that the Limon gold-silver discovery, within the Bramaderos Project, is continuing to grow, with more mineralisation identified surrounding the Central Shoot and up to 1km away. In response, Sunstone Managing Director Malcolm Norris said, "These results open up more new areas for drilling and enlarge our target zone." Shares are trading flat at 1.7 cents.
Sunstone Metals (ASX: STM) 宣布，在布拉马德罗斯项目内发现的利蒙金银矿产量持续增长，在Central Shoot周围以及1公里以外发现了更多的矿化区。对此，Sunstone董事总经理马尔科姆·诺里斯说：“这些结果为钻探开辟了更多新的区域，并扩大了我们的目标区域。”股价持平至1.7美分。
Chimeric Therapeutics (ASX:CHM) announced that the 1st patient has been dosed in the Phase 1B CHM 1101 in their brain cancer clinical trial. The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data. Shares are trading flat at 2.9 cents.
Chimeric Therapeutics (ASX: CHM) 宣布，在脑癌临床试验中，第一位患者已进入1B期CHM 1101给药。1B期临床试验建立在最近的阳性1A期临床数据基础上。股价持平至2.9美分。
